BioCardia (BCDA) announced the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia’s CardiAMP Heart Failure II Trial: A Promising Update for Investors
- BioCardia’s Innovative Stem Cell Therapy Trial for Heart Failure: Key Updates and Market Impact
- BioCardia Sets Record Date for Annual Meeting
- BioCardia Regains Nasdaq Compliance, Secures Continued Listing
- BioCardia regains compliance with Nasdaq listing requirements